Pulmatrix
PULM----
Pulmatrix (PULM)
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory disease...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Pulmatrix Analyst Rating
View MoreForecast & Rating
Nov 13, 2023Price forecast
$10.00506.06%
Forecast & RatingBuy
1analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- prnewswire · Jul 10 at 12:40 PM
13:38 ETSHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN
- benzinga_article · Jun 18 at 04:06 PM
12 Health Care Stocks Moving In Thursday's After-Market Session
- Earnings Watch · May 15 at 07:22 AM
Pulmatrix | 8-K: FY2026 Q1 Revenue: USD 0
- StockTitan · May 14 at 11:20 PM
Pulmatrix Announces First Quarter 2026 Financial Results | PULM Stock News
- biopharmadive · Mar 27 at 07:01 PM
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
- benzinga_article · Mar 26 at 10:10 AM
Pulmatrix shares are trading lower after the company announced it will acquire Eos, a developer of novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases.
